Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2024-03-13 Director's Dealing
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a regulatory filing in South Korea (DART system) used to disclose insider trading or changes in shareholding by major stakeholders. This falls under the category of 'Director's Dealing' (DIRS) as it details share transactions by a major shareholder (Bionote, Inc.) in the issuing company (Eubiologics).
2024-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for the 14th Annual General Meeting of Eubiologics. It contains the meeting agenda, details on voting procedures, and management information (governance, board activities, and business overview). This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on agenda items such as financial statement approval, director appointments, and remuneration limits.
2024-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation & Information Statement) used to solicit votes from shareholders for an upcoming Annual General Meeting. It contains the meeting agenda, details on how to vote (electronic/written), and financial statements for the fiscal year. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used when a major shareholder or executive changes their stake in a company. Since the document details a change in shareholding by a major shareholder (Bionote, Inc.) in the issuer (Eubiologics), it falls under the category of a Major Shareholding Notification.
2024-03-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Eubiologics. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the election of directors and auditors. This type of document is a standard proxy solicitation material used to inform shareholders of meeting details and request their participation/votes, fitting the definition of Proxy Solicitation & Information Statement (PSI).
2024-03-06 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. This type of corporate action regarding capital structure and equity-based compensation is classified as a regulatory filing related to share issuance/capital changes.
2024-03-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.